美国镭学会可手术食管及胃食管结合部腺癌适用标准执行摘要
美国镭学会胃肠道专家组采用PRISMA系统综述与改良Delphi共识法,评估可手术非转移性食管或胃食管结合部腺癌的新辅助和/或辅助治疗方案。针对cT3和/或cN+(Siewert I-II)患者,专家组最强烈推荐新辅助放化疗;cT2N0M0伴高危特征者通常适合新辅助放化疗;未接受新辅助治疗而pN+者通常适合辅助放化疗。
要点
- cT3和/或cN+食管或GEJ腺癌(Siewert I-II)最强烈推荐新辅助放化疗。
- cT2N0M0伴高危特征者,新辅助放化疗通常合适。
- 未接受新辅助治疗而pN+者,辅助放化疗通常合适。
核心结论
- 对于可手术非转移性食管或胃食管结合部腺癌,专家组基于系统综述和改良Delphi共识给出了新辅助及辅助治疗的适用性推荐。
研究设计与样本
- 美国镭学会胃肠道专家组采用PRISMA方法系统检索Ovid Medline、Cochrane Central和Embase数据库2009至2019年的II期随机对照试验、III期随机对照试验及荟萃分析,并通过改良Delphi共识法对4类代表性临床场景的治疗适用性进行评分。
主要发现
- 对于医学上可手术的非转移性cT3和/或cN+食管或胃食管结合部腺癌(Siewert I-II)患者,专家组最强烈推荐新辅助放化疗。
- 对于cT2N0M0伴高危特征的患者,专家组推荐新辅助放化疗为通常合适。
- 对于病理证实淋巴结阳性(pN+)且未接受任何新辅助治疗的患者,专家组推荐辅助放化疗为通常合适。
- 指南评估了多种剂量分割方案和靶区范围的适用性。
关键数值与推荐
- cT3和/或cN+(Siewert I-II)可手术非转移性食管或GEJ腺癌:最强烈推荐新辅助放化疗。
- cT2N0M0伴高危特征:新辅助放化疗通常合适。
- pN+且未接受新辅助治疗:辅助放化疗通常合适。
临床怎么用
- 临床可依据cTNM分期和Siewert分型,参照本适用标准选择新辅助放化疗、辅助放化疗或手术等治疗策略。
- 对cT3和/或cN+(Siewert I-II)患者应优先考虑新辅助放化疗。
- 对cT2N0M0伴高危特征者可选新辅助放化疗。
- 对未接受新辅助治疗的pN+患者可选辅助放化疗。
局限性
- 食管癌化疗和/或放疗方案仍在演变,存在许多活跃研究领域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Limited guidance exists regarding the relative effectiveness of treatment options for nonmetastatic, operable patients with adenocarcinoma of the esophagus or gastroesophageal junction (GEJ). In this systematic review, the American Radium Society (ARS) gastrointestinal expert panel convened to develop Appropriate Use Criteria (AUC) evaluating how neoadjuvant and/or adjuvant treatment regimens compared with each other, surgery alone, or definitive chemoradiation in terms of response to therapy, quality of life, and oncologic outcomes. METHODS AND MATERIALS: Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) methodology was used to develop an extensive analysis of peer-reviewed phase 2R and phase 3 randomized controlled trials as well as meta-analyses found within the Ovid Medline, Cochrane Central, and Embase databases between 2009 to 2019. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in 4 broadly representative clinical scenarios through a well-established consensus methodology (modified Delphi). RESULTS: For a medically operable nonmetastatic patient with a cT3 and/or cN+ adenocarcinoma of the esophagus or GEJ (Siewert I-II), the panel most strongly recommends neoadjuvant chemoradiation. For a cT2N0M0 patient with high-risk features, the panel recommends neoadjuvant chemoradiation as usually appropriate. For patients found to have pathologically involved nodes (pN+) who did not receive any neoadjuvant therapy, the panel recommends adjuvant chemoradiation as usually appropriate. These guidelines assess the appropriateness of various dose-fractionating schemes and target volumes. CONCLUSIONS: Chemotherapy and/or radiation regimens for esophageal cancer are still evolving with many areas of active investigation. These guidelines are intended for the use of practitioners and patients who desire information about the management of operable esophageal adenocarcinoma.
引用
- Anker CJ, Dragovic J, Herman JM, et al. Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines. Int J Radiat Oncol Biol Phys. 2020. PMID: 32858113. doi:10.1016/j.ijrobp.2020.08.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。